Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Low-dose Dasatinib as First-line Treatment for Chronic Myeloid Leukemia

Our goal is to demonstrate that 50mg of dasatinib is as effective as the full dose to induce molecular response as first line therapy in CML.

We will give 50mg of dasatinib daily since the diagnosis for up to 6 months, for the first 2-4 weeks we will evaluate hematic biometry to registry hematic response, at months 3 and 6 a BCR/ABL PCR will be taken to evaluate molecular response.

Inclusion Criteria:

• Diagnosis of BCR-ABL positive CML in early chronic phase CML. Except for hydroxyurea, patients must have received no or minimal prior therapy, defined as <2 weeks (14 days) of prior FDA approved TKI.
• ECOG performance of 0-2
• Adequate end organ function, defined as the following: total bilirubin <1.5x ULN, SGPT <2.5x ULN, creatinine <1.5x ULN.
• Patients must sign an informed consent indicating they are aware of the investigational nature of this study.

Exclusion Criteria:

• NYHA cardiac class 3-4 heart disease or previous pleural effusion.
• Pregnancy and lactation
• Patients with active, uncontrolled psychiatric disorders